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Letter to Editor 
Response to: Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 
infection: A systematic review and meta-analysis  






Meta-analysis       
We read with interest the recent meta-analysis published in this 
journal by Kumar et al. [1] about the efficacy and safety of hydroxy-
chloroquine (HCQ) in patients affected by coronavirus disease 2019 
(COVID-19). Included studies in the final analysis for therapeutic effect 
of HCQ were 14, with 10 randomized controlled trials, and 4 
non-randomized prospective cohort studies. The conclusions of this 
analysis reported no evidence of mortality increase for patients treated 
with HCQ in comparison to the control group in the non-randomized 
studies, while a RR = 1.10 was reported in hospitalized patients. How-
ever the Authors reported in the Supplementary Table 3 the subgroup 
analysis by “mild/moderate disease”, but in the method section was not 
defined if this classification was made by clinical or other laboratory 
parameters; it’s reasonable that the severity criteria were different 
among the included studies, and the dichotomous analysis “mild/mo-
derate” could be arbitrary; in our opinion this analysis should be more 
correctly performed by a meta-regression using the P/F values at the 
admission as independent moderator for severity; the Authors reported 
themselves in the “Results” section that in the majority of cases HCQ was 
given in patients with severe disease; moreover, the HCQ dose and 
treatment duration were not analyzed as moderator in the subgroup 
analysis: this aspect represents in our opinion a serious lack in this 
meta-analysis because an hypothetical side-effect of HCQ should be 
demonstrated by a meta-regression analysis, where the risk of toxicity 
should be related to the increase of dose measured by a continuous 
values. The same objection could be proposed for the age of enrolled 
subjects, the treatment duration time (days) with HCQ, presence of 
comorbidities such as QT prolongation or other known or detected ar-
rhythmias. It seems really unexpected that in two important and 
different studies as the RCT by Cavalcanti et al. [2] and the retrospective 
study by Million et al. [3] no significant adverse events or mortality risk 
were associated with the HCQ + azithromycin combination. Further-
more, another important study was excluded from this meta-analysis 
and is focused on the role of low-dose of HCQ (2400 mg administered 
in 5 days) during the COVID-19 disease with a significant higher mor-
tality in the patients not treated with HCQ, despite an early time to 
admission in the hospital [4]. Considering the large amount of available 
data about the safety of HCQ at the standard dose in other well known 
illness as malaria or rheumatic diseases, it is to be assumed that higher 
doses of HCQ (>2.4g during the 5 days) can lead to toxicity also due to 
the longer detectable plasmatic level of this drug (>50 days). The main 
limitation of this meta-analysis was the lack of sub-group analysis ac-
cording to different HCQ dose and treatment duration; this is a crucial 
aspect in our opinion, because elderly patients with some comorbidities 
have a major risk of acute heart failure, ischemia and arrythmia in 
COVID-19 [5]. For this reason, the analysis of the treatment duration 
and the overall dose of HCQ is essential to understand the real proar-
rhythmic role without QTc prolongation or in presence of other 
COVID-19 related myocardial injury. 
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Saint Andrea Hospital, Unit of Infectious Diseases, Vercelli, Italy 
* Corresponding author. 
E-mail address: lucio.boglione@uniupo.it (L. Boglione). 
Letter to Editor                                                                                                                                                                                                                                  
